Chip Hance is CEO of Regatta Medical, headquartered in Chicago, IL, and focuses on acquiring companies and assets in either the products or services areas of the medical device industry as part of a strategy to build a market-leading company in the space. Mr. Hance most recently served as Chief Executive Officer of Creganna Medical, a leading supplier of contract manufacturing services for medical devices. In 2012-13, Hance was an Entrepreneur-in-Residence at CDRH within the FDA. He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S. Prior to his FDA experience, Hance was most recently President of Abbott Vascular, the cardiovascular device division of Abbott. Over a decade in interventional cardiology at Abbott Vascular, Hance led the organization to global leadership in the drug-eluting stent market through the launch of Xiencein the U.S., Japan and China. Hance also led the development and CE marking of Absorb, a bioabsorbable scaffold for the treatment of coronary disease and the acquisition and international expansion of Mitraclip, a percutaneous mitral valve repair device. Hance earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.